Podcasts about ALK

Urvashi Prasad has spent the last 15 years trying to make the world a kinder, fairer, and better place through her policy-based interventions in heathcare. Armed with degrees from Cambridge and LSTH, she worked as a director at NITI Aayog, and was awarded the India-UK Achievers Award. In addition to sharing principles and frameworks for building meaningful careers in public policy, Urvashi opens up about losing her beloved father and being diagnosed with cancer soon after. We admire her resilience and are proud to share her story with you. Here you will learnHow governments attempt to address systemic challenges in sectors like healthcareHow young professionals can carve out interesting and impactful careers in public policy How to make sense of life when you lose your beloved parent and are diagnosed with cancerUrvashi Prasad is a public health and policy advisor with over 15 years of leadership across government, academia, and grassroots innovation. As Director in the Office of the Vice Chairperson at NITI Aayog, India's apex policy think tank, she helped shape the country's COVID-19 response strategy, monitor Sustainable Development Goals in real time, and spearhead national programs advancing public health, gender equity, and social inclusion.A co-author of India's first Voluntary National Review presented at the UN High-Level Political Forum in 2017, Urvashi's policy insights have been featured in 150+ publications globally. She is also the British Council's UK Alumni Ambassador for SDG 10, an Honorary Professor at De Montfort University, UK, and a member of the World Economic Forum's Expert Network. Her accolades include the India-UK Achievers Honors and recognition among India's most influential women. In 2023, she founded Spcace by Urvashi, a pioneering platform amplifying patient voices.Diagnosed with Stage 4 ALK-positive lung cancer at age 35, Urvashi now brings lived experience to the policy table --challenging invisibility in cancer discourse and driving recognition of under-researched malignancies in young adults. Her advocacy bridges science, storytelling, and systemic reform.She holds a master's in public health from the London School of Hygiene & Tropical Medicine, an MPhil in Bioscience Enterprise from Cambridge University, and a Bachelor's in Biological Sciences (Genetics) from the University of Birmingham, UK. In 2024, Urvashi received an honorary doctorate for her work in public health and policy.

This is an edited version of an interview that first appeared in episode 79 in September 2020. Ian Duff worked as a keeper at 13 Scottish lighthouses between 1976 and 1992. He spent about five years at Skerryvore, a remote station off the west coast of Scotland. He also spent about five years at Duncansby Head Light Station at the most northeasterly point of the British mainland. Ian Duff at St. Abbs Head Lighthouse in Scotland. Photo by Jeremy D'Entremont. Ian remained involved with lighthouses after his retirement as a keeper. He became the president of the Association of Lighthouse Keepers, or the ALK, an organization that provides a forum for everyone interested in lighthouses, lightships, and maritime aids to navigation. When Ian passed away last year, a large collection of his photographic slides were donated to the Museum of Scottish Lighthouses, along with lighthouse artifacts. Skerryvore Lighthouse (U.S. Lighthouse Society)

Notas del Show: En este episodio cubrimos los eventos más relevantes antes de la apertura del mercado: • Wall Street se mantiene plano ante foco en aranceles: Futuros sin dirección clara: $SPX y $US100 sin cambios, $INDU -0.2 %. El mercado sigue digiriendo las cartas de tarifas de Trump y el impacto político. Hoy se publican solicitudes de desempleo (consenso: 245K). • Delta sorprende y eleva previsión anual: $DAL sube +10 % premarket tras superar estimaciones del 2T con buenos márgenes en servicios premium y fidelidad. También suben $AAL, $UAL, $LUV, $JBLU y $ALK entre +2 % y +7 %. • MP Materials se dispara con apoyo del Pentágono: $MP +38.9 % tras anunciar una nueva planta de imanes y expansión en Mountain Pass con respaldo multimillonario del Departamento de Defensa. Refuerza independencia de EE.UU. frente a tierras raras extranjeras. • Palantir eleva guía y apunta a liderazgo AI: $PLTR mantiene rating Outperform en Wedbush, que sube su precio objetivo a $160. Destacan su potencial para superar los $1B en ingresos por IA y su papel clave en EE.UU. y la OTAN. • OpenAI desafía a Google con navegador AI: OpenAI, respaldada por $MSFT, lanzará un navegador conversacional para competir con Chrome y redirigir el uso de la web a través de IA. Busca integrar ChatGPT en la experiencia diaria y captar cuota publicitaria. Una jornada con foco en innovación, defensa estratégica y tecnología disruptiva. ¡No te lo pierdas!

In this JCO Article Insights episode, host Peter Li summarizes "Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST" by Pérol et al, published April 03, 2025, followed by an interview with first author, Dr Maurice Pérol. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this episode of JCO Article Insights. I am Dr. Peter Li, JCO's editorial fellow, and today I am joined by Dr. Maurice Pérol on “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” by Pérol et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. Before we start our interview, I want to give our listeners a quick summary of the TRUST study. For those tuning in, the TRUST study is a phase II, single-arm, open-label, nonrandomized, multicenter trial looking at the efficacy and safety of a novel, next-generation ROS1 TKI, taletrectinib, in advanced ROS1-mutated non–small cell lung cancer. While a relatively rare mutation, the prevalence of ROS1 mutations ranges from 0.9% to 2.6% of patients, with a third of patients presenting with brain mets at diagnosis.Current FDA-approved therapies include crizotinib, entrectinib, and repotrectinib, which have varying degrees of efficacy, in-coming with trade-offs in CNS penetrance and safety with newer generations, particularly in the realm of neurological side effects, highlighting an unmet need in this arena. A total of 273 patients with advanced non–small cell lung cancer with confirmed ROS1 mutation were recruited for this study. 160 patients were TKI-naive, while 113 were TKI-experienced with either crizotinib or entrectinib. Patients with asymptomatic brain mets were also allowed to enroll. In the TKI-naive arm, the median age was 57, with 91% of patients having stage IV disease, 20% having no more than one cycle of chemo, and 23% having brain mets at baseline. In the TKI-experienced arm, the median age was 53, with 97% having stage IV disease, 37% having received prior chemo, and about 50% having brain mets. Furthermore, about 10% of the study population had received entrectinib, while more than 90% had received crizotinib. About 10% had a known G2032R acquired resistance mutation. Taletrectinib was dosed at 600 mg daily until disease progression or unacceptable toxicities. The primary endpoint was overall response rate, with secondary endpoints being disease control rate, duration of response, time to response, and progression-free survival. For those with brain mets, intracranial overall response rate and disease control rate were also assessed. Median follow-up time was about 21 months in both cohorts. In the TKI-naive cohort, the overall response rate was 89%, with 8 patients achieving a complete response. Disease control rate was 95%, with a median duration of response of 44.2 months. Time to treatment response was about 1.5 months. Median progression-free survival was 45.6 months, with 52.6% not having progressed at 3 years. While overall survival data were immature, 66% of patients were still alive at 3 years. In the pretreated cohort, overall response rate was 56%, with 5 patients achieving a complete response. Overall response rate was 53% for those who were crizotinib-pretreated and 80% for the entrectinib-pretreated patients. Disease control rate was 88%, and median duration of response was about 16.5 months. Time to treatment response was also 1.5 months, and median progression-free survival was 9.7 months. Median overall survival was not reached, but 77.5% of patients were still alive at 1 year. Responses were consistently seen across subgroup analyses. 17 TKI-naive and 32 TKI-pretreated patients had measurable brain mets. In the TKI-naive arm, intracranial overall response rate was 77%. Disease control rate was 88%, and duration of response was 15 months. In the TKI-pretreated arm, intracranial overall response was 66%, with one patient achieving complete response. The disease control rate was 94%, and duration of response was about a year. For the 13 patients who had a known G2032R mutation, a 62% response rate was noted. Most common treatment-related side effects were AST/ALT elevation, nausea, and vomiting, with most being grade 1 or 2. Most common neurological side effects were dizziness, dysgeusia, and headache. Again, most were grade 1. QTc prolongation is another important adverse event to note, occurring in about 18% of all patients. Discontinuation rate from treatment was only 7%. There were three treatment-related deaths in this study: one from hepatic failure, one from pneumonia in the naive arm, and one from liver dysfunction in the pretreated arm. Dr. Peter Li: Maurice, thank you so much for joining us today to talk about your paper. Would you mind just giving yourself a brief introduction to the listeners out there of who you are? Dr. Maurice Pérol: So, my name is Maurice Perol. I'm a thoracic oncologist working in the Cancer Center of Lyon in France. And I'm involved in clinical research in thoracic oncology. I've been involved for many years now. Dr. Peter Li: Okay. And for listeners out there, don't forget, he's also the primary author of the paper that we just talked about. So, Maurice, let's begin. Can you tell our listeners what is the significance of your study? Dr. Maurice Pérol: Well, the results of these two large phase II studies - TRUST-I, which has been conducted in China, and TRUST-II, which was a global, worldwide phase II study - so, the results place taletrectinib as the TKI with the most favorable efficacy-tolerability ratio of the available ROS1-targeting TKIs, especially in frontline therapy. And this is based on the response rate, which was very impressive, the CNS penetration with a great CNS activity, the duration of response with a compelling 45 months median PFS in frontline setting. The level of activity in pretreated patients after crizotinib or entrectinib was also impressive and similar to that of repotrectinib, for example, but with a more favorable neurological tolerance profile. The toxicity is mainly represented with grade 1 or 2 transaminase elevation, but without clinical symptoms, and GI toxicity, but mainly grade 1 and 2. The neurological toxicity is low, especially for dizziness, showing that taletrectinib spares TrKB in a large part. And finally, there is also a decrease in toxicity over time, especially for GI toxicity and liver toxicities, which allows a very long and a prolonged administration, which is very important in this setting. Dr. Peter Li: These are all excellent points. Can you tell the listeners if there are any limitations that we should be concerned about, about this study? Dr. Maurice Pérol: Sure. This data comes from single-arm phase II studies. So, this is not comparative data. And a phase III trial, which compares taletrectinib to crizotinib, is ongoing to evaluate the superiority of taletrectinib over the standard of care. Another limitation comes from the lack of systematic brain imaging at each tumor evaluation in patients without brain metastases at baseline, not allowing to assess the intracranial PFS in all patients, and which did not allow us to assess the CNS protective issue from taletrectinib, especially in patients without brain metastases at baseline. Dr. Peter Li: Another question that I have is, with this novel TKI now available, how would you recommend the sequencing of these drugs? Would you start with someone on an alternate TKI and then reserve taletrectinib second line or later? Or would you use it upfront? Or does it depend? Dr. Maurice Pérol: Well, it is a very important question, as we have now different available TKIs. Looking at the efficacy-toxicity balance, I would strongly favor the use of taletrectinib in frontline setting, in first line. The response rate, the CNS activity, the duration of response with a very compelling 45 months median PFS, and moreover, the good tolerance profile over time are strong arguments in favor of giving taletrectinib in frontline. Generally speaking, the use of the most active agent as frontline treatment in lung cancer depending on an oncogenic addiction is probably the best way to improve the patient's outcome. This is true for patients with EGFR mutation, for patients with ALK fusions, and this is probably also true for patients with ROS1 fusion. So, I would probably argue in favor of a frontline use of taletrectinib. Dr. Peter Li: Listeners are going to ask, well, if you use taletrectinib upfront, then what are you going to use second line once they progress? Dr. Maurice Pérol: Well, we have some new compounds which are under development today. For example, the NVL-520, which is a very interesting compound, which seems also to be active in case of resistance mutation. But I do think that we have to use the best-in-class TKI in frontline because, you know, the extension of PFS after acquired resistance you can obtain with a second-line TKI is always shorter than the benefit you can obtain by using the most active agent in frontline. And this is true for the majority of oncogenic addiction in lung cancer. Dr. Peter Li: That makes sense. I also noticed that cognitive impairment wasn't listed in the safety table. Is that not an issue that you've observed at all with taletrectinib, or is it still an issue but less so because, like you mentioned earlier, because of its higher selectivity? Dr. Maurice Pérol: Well, this is a good question because we have some ROS1-targeting TKIs like repotrectinib, entrectinib, and even lorlatinib, with some neurological adverse events and some cognitive issues. Taletrectinib is a very selective ROS1-targeting TKI, and it spares very well the TrKB, for example, explaining that we did not observe any cognitive impairment with taletrectinib in the TRUST study, showing also with the low level of other neurological adverse events, dizziness, dysgeusia, for example, the high selectivity of the compound and the preservation of TrKB. So, this is very important when you consider the long duration of treatment in those patients with ROS1 fusion. If you have to take a drug for more than 2, 3, or 4 years, of course, the neurological adverse events are very important, and they can clearly impair the quality of life. So, this is a very important point, the very low level of neurological toxicity of taletrectinib. Dr. Peter Li: And I think that goes to say why you would favor using it frontline as well compared to entrectinib or repotrectinib. Last question that we have for you is: well, what's next? You mentioned there's a phase III trial comparing it to crizotinib. I think one of the questions that a lot of us would have is: why not compare it to one of the newer agents as a comparator arm? Dr. Maurice Pérol: Well, this is a good question. Crizotinib remains the standard of care in many countries for ROS1-positive advanced non–small cell lung cancer outside of the US, especially in Europe, and in particular in patients who do not have brain metastases at diagnosis. Entrectinib has a better CNS penetration, but it did not achieve a better PFS than crizotinib in phase I/II trials, and clearly, it has a less favorable tolerance profile with weight gain, edema, and neurological adverse events. Repotrectinib has overall a level of activity which seems close to that of taletrectinib. So, it makes it difficult to consider a comparative trial that would, for example, test taletrectinib in comparison with repotrectinib because this kind of study would need a very large number of patients and a very late readout. Considering if you have a median PFS of more than 3 or 4 years, it would be very difficult to have results in before 4-5 years. So, from a pragmatic point of view, the comparison of taletrectinib to crizotinib is probably the best way to evaluate in a phase III setting the level of activity of taletrectinib, especially in the CNS, because this study will probably allow us to assess the CNS protective effect of the compound for patients without brain metastates at baseline. So, I think probably it's a pragmatic study that will allow us to confirm the high level of activity and the good tolerance profile of taletrectinib. Dr. Peter Li: Well, thank you, Maurice, so much for speaking about the JCO article, “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” and for all your valuable input today. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Terwijl in mei en juni de examens in volle gang zijn, ervaren veel jongeren tegelijkertijd de piek van het pollenseizoen. Naar schatting heeft 28% van de 15- tot 19-jarigen last van hooikoorts, en dat gaat niet ongemerkt voorbij. Uit onderzoek* van ALK blijkt dat 50% van de ouders denkt, dat de allergieklachten de examenprestaties van hun kind negatief beïnvloeden. Hooikoorts veroorzaakt klachten zoals niezen, een verstopte neus, jeukende ogen en slaapproblemen. Juist die verstoorde nachtrust baart ouders zorgen: meer dan 60% maakt zich zorgen over het slaapgebrek van hun kind en het effect daarvan op cognitieve prestaties.  Tieners hebben tussen de acht en tien uur slaap nodig om optimaal te kunnen functioneren tijdens examens”, zegt kinderarts-allergoloog Monique Gorissen. “Als die slaap wordt verstoord door allergieklachten, missen ze belangrijke diepe slaapfases die nodig zijn voor concentratie en geheugen. Presentator Ron Lemmens sprak met Medisch Directeur Elena Uss. Elena is een ervaren medisch professional met meer dan vijftien jaar ervaring in de farmaceutische industrie. Ze heeft verstand van medische zaken, klinisch onderzoek, recht- en regelgeving binnen de farmacie, market access en vergoedingsprocessen, en kent een grootnetwerk. Tijdens de non-stop uren op GoodLIFE Radio hoor je de meeste interessante updates over gezondheid en leven. Wat zijn de mooie initiatieven? Wat is er anders in deze onwerkelijke tijden? Laat het ons weten! De podcast is na de uitzending terug te luisteren via alle bekende podcast platforms (onder meer Spotify, Apple Podcasts en Google Podcasts).

Featuring perspectives from Dr Jessica J Lin and Dr Joel W Neal, including the following topics: Introduction: Actionable Genomic Alterations (0:00) ALK (9:49) ROS1 (22:22) HER2 (31:00) RET (38:52) NTRK (45:30) MET (46:31) Novel Targeted Strategies (49:09) BRAF (54:19) KRAS G12C (55:38) CME information and select publications

Vi har med oss legen Oscar Ohene Asante, Øre-nese-hals-spesialisten – og ikke minst en dedikert løper selv!Lyse morgener, grønne parker og nye treningsmuligheter lokker oss ut i det fri. Men for en pollenallergiker kan denne tiden på året kjennes mer som en kamp enn nytelse. Trøtthet, kløende øyne og rennende nese er ikke akkurat drømmeselskap på trening – så hvordan holder man koken uten at allergien får overtaket?I denne episoden av Treningspodden får du svaret! Oscar forklarer hva pollenallergi egentlig er, hvilke symptomer som er de vanligste – og viktigst av alt: hvordan du kan lindre plagene. God lytt! Denne episoden er laget i samarbeid med ALK – et globalt, forskningsdrevet selskap som jobber med forebygging, diagnostisering og behandling av allergi. ALK står også bak nettsiden pollenkontroll.no, hvor du finner nyttig informasjon og verktøy for å få bedre kontroll på hverdagen med pollenallergi. Hosted on Acast. See acast.com/privacy for more information.

Her hafta Canlı Yayında sinema ve televizyon gündemini konuşuyoruz, ilgimizi çeken konuları tartışıyoruz.00:00 | Giriş07:15 | Mission: Impossible - The Final Reckoning26:20 | Murderbot28:10 | The Last of Us - S2E6 43:30 | Son 25 Yılın 10 Hayal Kırıklığı 1:19:45 | Güncel Cannes eleştiri tablosu1:39:30 | Cannes'da Ayakta En Çok Alkışlanan Filmler1:44:25 | Cannes Filmleri  1:47:55 | Sinema Gündemi: Haber Turu1:57:40 | Fatih Akın'ın Ayşe Barım Açıklaması 1:59:55 | Martin Scorsese Belgeseli Yolda2:00:00 | Jodie Foster'dan Genç Oyunculara Eleştiri2:05:05 | Damien Chazelle'in Yeni Filminin Kadrosu2:05:05 | Adam Curtis & A242:07:20 | David O. Russell ve Yine Olaylı seti2:08:05 | Blockbuster Filmler2:10:40 | MUBI'de Bu Hafta

Hadîs ricâlini tenkîd noktasında büyük bir otorite olan (ehlü'l-istikrâ) Zehebî'nin söylemiş olduğu en doğru sözlerden birisi, Siyer-u A'lamî'n-nübelâ isimli eserinde Irak'ın fakihi Allâme İmâm Hammad b. Ebû Süleyman (r.âleyh)'in hayat hikâyesini aktarırken kullanmış olduğu şu ifâdelerdir: “Kûfelilerin en fakihi Hz. Alî (r.a.) ve İbn Mes'ûd (r.a.)'dir. Bu iki sahâbenin en fakih öğrencileri Alkâme, Alkâme'nin en fakih öğrencisi İbrâhîm en-Nehaî, Nehâî'nin en fakih öğrencisi Hammad, Hammad'ın en fakih öğrencisi ise Ebû Hanîfe (r.a.)'dir. Ebû Hanîfe (r.a.)'in en fakih öğrencisi Ebû Yusuf'tur. Ebû Yusuf'un öğrencileri dünyanın dört bir tarafına yayılmışlardır. Bunların en fakihi Muhammed b. el-Hasen'dir. İmâm Muhammed'in en fakih öğrencisi ise Ebû Abdullah eş-Şâfiî'dir.Allâh (c.c.) tamâmına rahmet eylesin.” Zehebî aynı eserinin bir başka yerinde İmâm Ebû Hanîfe (r.a.)'in hayatını anlatırken şu ifâdeleri kullanmaktadır: “İmâm, dînin fakihi ve Irak'ın âlimi Ebû Hanîfe (r.a.)… Hadîs ilmine önem verdi. Bu uğurda yolculuklar yaptı. Fıkıh, rey ve reyin kapalı noktalarını tetkik etmede zirvedir. Bu konuda bütün insanlar ona minnet borçludur.” Zehebî aynı eserinin bir başka yerinde Ebû Hanîfe (r.a.) hakkında “Fıkıhta ve fıkhın inceliklerinde önde gelen bir âlim olduğu herkesçe kabûl edilen bir gerçektir. Bu noktada hiçbir kuşkuya yer yoktur” demektedir.(Muhammed Abdurreşid En-Nûmanî, İmâm-ı Azam Ebû Hanîfe (r.a.)'in Hadis İlmindeki Yeri, s. 44-45)BIR FIKIH KAIDESI ÖĞRENELIM!Bir kimse iki veya daha fazla secde ayetini aynı mecliste okusa veya secde ayetini okusa ve akabinde aynı yerde başka işle meşgul olsa, mesela birçok şey yese veya yatarak uyusa yahut da kadın ise bebeğini emzirse, sonra da yine aynı yerde aynı ayeti okusa iki kere secde etmesi gerekir.(Misvâk Neşriyat, Eşref Ali Et-Tehanevi, Hanefi İlmihali, s.211)

Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for metastatic non-small cell lung cancer (NSCLC) with actionable mutations in frontline therapy. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins Hospital. In this episode, we covered: •⁠  ⁠Common EGFR mutations and the latest treatment options, including osimertinib, amivantamab, and chemotherapy combinations. •⁠  ⁠The importance of comprehensive NGS testing and the need for retesting at progression. •⁠  ⁠Insights into managing side effects associated with various therapies, including the proactive management of cutaneous toxicities. •⁠  ⁠Treatment strategies for less common mutations such as ALK, ROS1, BRAF, and RET, along with their respective targeted therapies. •⁠  ⁠The role of immunotherapy in specific mutations and the importance of patient choice and preferences in treatment decisions. Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice. YouTube: https://youtu.be/LMYDAjZcn5w Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

A Biomarker Dialogue Between Patient and Scientist HOST: Hildy Grossman, CO-HOST: Jordan Rich GUEST: Marc Muskavitch, PhD, ALK+ & Zachary Rogers, PhD, Research Fellow, Koch Institute at MIT This episode features a powerful conversation between two scientists, one now navigating life as a Stage 4 ALK+ lung cancer patient. Most lung cancer patients only learn … Continue reading Living with ALK+: Diagnosis, Treatment, & Hope →

Fuld gang i rapporteringen fra de danske selskaber tirsdag, der bringer nyt fra Vestas, ISS, Coloplast, ALK, DFDS og - sidst på dagen - Demant. Millionærklubben tjekker stemningen og tager desuden en tur forbi oliepriserne, der efter sidste nyt fra OPEC+ viger i pris. I studiet: Lau Svenssen og Bodil Johanne Gantzel.See omnystudio.com/listener for privacy information.

Hvordan vet du om barnet ditt har pollenallergi – eller om det bare er en lang vårforkjølelse? Hva er første steg i behandling, og hva kan du gjøre i hverdagen for å lindre plagene?Barnelege og allergiforsker Tonje Reier-Nilsen forklarer hvordan pollenallergi kan påvirke barnets livskvalitet – og hvorfor tidlig diagnose og riktig behandling kan gjøre en stor forskjell.Episoden er laget i samarbeid med ALK, et forskningsdrevet legemiddelselskap som jobber med forebygging, diagnostisering og behandling av allergi – og driver nettsiden www.pollenkontroll.no. Hosted on Acast. See acast.com/privacy for more information.

Ostenta el récord de España de halterofilia en su categoría, ha participado en cinco juegos paralímpicos y su currículum en campeonatos de España, Europa y el mundo es interminable. Loida Zabala es todo un ejemplo de superación. Una mielitis transversa la hizo vivir en silla de ruedas y, a finales de 2023, fue diagnosticada de cáncer de pulmón ALK positivo. Eso no le impidió participar en los Juegos Paralímpicos de Londres. Loida nos cuenta su experiencia y cómo el deporte le ayuda en el día a día en un episodio en el que contamos con público en las oficias de Roche Farma España. 

Lorlatinib is reshaping first-line treatment for ALK-positive NSCLC—but its distinct side effect profile demands proactive, personalized management. In this episode,  Stefanie Houseknecht, PharmD, BCOP (Johns Hopkins Medicine) and Monica Chintapenta, PharmD, BCOP (Parkland Health)share how they're navigating real-world use of lorlatinib, from interpreting long-term data to counseling patients through CNS effects, weight gain, and metabolic challenges.Highlights:Why lorlatinib is gaining traction in first-line ALK+ NSCLCWhat the long-term CROWN data really means for patient outcomesHow to handle tricky side effects like cognitive changes, weight gain, and hyperlipidemiaReal-world tips for patient counseling and supporting adherenceThe importance of catching drug interactions and staying ahead on labsHow pharmacists are shaping care across the oncology teamBonus: Hear how our guests find balance beyond the clinic, whether in the garden or on the Boston marathon course. About Our Guests:Monica completed her Doctor of Pharmacy at Texas Tech University Health Sciences Center and went on to complete PGY-1 and PGY-2 residencies at Tufts Medical Center and Froedtert & the Medical College of Wisconsin, respectively. At Parkland, she supports outpatient hematology/oncology care and leads quality initiatives.   Stefanie earned her PharmD from the University of the Pacific, followed by PGY-1 and PGY-2 residencies at Palomar Medical Center and the University of California-San Diego. Her work focuses on thoracic malignancies, access to oral targeted therapies, and patient outcomes. She is active in the International Association for the Study of Lung Cancer and serves as a preceptor to pharmacy trainees across the Mid-Atlantic.  

Våren förknippas ofta med glädje och livslust men för en allt för stor del av befolkningen är det faktiskt tvärtom. För pollen försämrar livskvalitén för allergiker som blir mindre produktiva, sjuka och får svårt att delta i sociala aktiviteter. Fast såhär behöver det faktiskt inte vara, det finns hjälp att få mot pollenallergi. I extrakursen i pollenallergi berättar Victoria Strand, som är överläkare och specialist i allergisjukdomar, varför man inte ska trivialisera sin pollenallergi, vilka behandlingsformer det finns och hur kan man hjälpa barn med jobbiga symtom.Avsnittet är ett samarbete med ALK, ett globalt, forskningsdrivet företag som arbetar med prevention, diagnostisering och behandling av allergi. ALK driver också hemsidan Pollenkoll.se och appen Pollenkoll. Hosted on Acast. See acast.com/privacy for more information.

This PER® Spectives™ featured podcast reviews the 22nd Annual Winter Lung Cancer Conference® held in January/February 2025. Multiple successive generations of ALK inhibitors have provided increasing benefits as first-line treatment for the thousands of patients with non-small cell lung cancer (NSCLC) that harbors rearrangements or mutations in the ALK gene. This program focuses on the practical aspects of managing patients with ALK-positive advanced or metastatic NSCLC, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Featuring an interview with Dr Justin F Gainor, including the following topics: Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00) Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38) Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32) Tolerability profile of lorlatinib (23:28) Review of clinical investigator survey results (37:08) Novel ALK inhibitors under clinical development (53:22) CME information and select publications

Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. CME information and select publications here.

Featuring a slide presentation and related discussion from Dr Justin F Gainor, including the following topics: Duration of responses observed with ALK inhibitors in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC) (0:00) Current role of other systemic therapy options for the treatment of ALK-positive mNSCLC; management of oligometastatic disease (8:38) Local therapy approaches for treating CNS disease in ALK-positive mNSCLC (18:32) Tolerability profile of lorlatinib (23:28) Review of clinical investigator survey results (37:08) Novel ALK inhibitors under clinical development (53:31) CME information and select publications

Are you up to date on the most optimal management of patients with early-stage ALK-positive non-small cell lung cancer (NSCLC)? Credit available for this activity expires: 3/24/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/preeclampsia-biomarker-screening-every-trimester-2025a100065r?ecd=bdc_podcast_libsyn_mscpedu

In today's episode, supported by Summit Therapeutics, we had the pleasure of speaking with Xiuning Le, MD, PhD, about the use of ivonescimab (SMT112) in patients with PD-L1–positive non–small cell lung cancer (NSCLC). Dr Le is an associate professor in the Department of Thoracic/Head and Neck Medical Oncology in the Division of Internal Medicine at The University of Texas MD Anderson Cancer Center in Houston. The phase 3 HARMONi-2 trial (NCT05499390) investigated ivonescimab vs pembrolizumab (Keytruda) in patients with locally advanced or metastatic, PD-L1–positive NSCLC without sensitizing EGFR mutations or ALK translocations. At the preplanned interim analysis, at a median follow-up of 8.7 months (IQR, 7.1-10.3), the median progression-free survival was significantly longer in the ivonescimab arm (n = 198) vs the pembrolizumab arm (n = 200), at 11.1 months (95% CI, 7.3-not estimable) vs 5.8 months (95% CI, 5.0-8.2), respectively (stratified HR, 0.51; 95% CI, 0.38-0.69; 1-sided P < .0001). The objective response rates were 50% (95% CI, 43%-57%) and 39% (95% CI, 32%-46%) in these respective arms. In our exclusive interview, Dr Le discussed the rationale for the HARMONi-2 trial, key findings from the study, and where these findings position the potential role of ivonescimab in the PD-L1–positive NSCLC treatment paradigm.

Tracey Ryniec, Zacks Value Stock Strategist, looks for stocks with high Zacks Rank and low PEG ratios. (0:30) - Can The PEG Ratio Help You Find Strong Value Stocks For Your Portfolio? (4:20) - Tracey's Top Stock Picks To Keep On Your Watchlist Right Now (24:30) - Episode Roundup: UAL, COOP, FOLD, ALK, AAL

Tracey Ryniec, Zacks Value Stock Strategist, looks for stocks with high Zacks Rank and low PEG ratios. (0:30) - Can The PEG Ratio Help You Find Strong Value Stocks For Your Portfolio? (4:20) - Tracey's Top Stock Picks To Keep On Your Watchlist Right Now (24:30) - Episode Roundup: UAL, COOP, FOLD, ALK, AAL Podcast@Zacks.com

308. TANYA CARMONA DANIELS UPDATES US ABOUT CHLORINE DIOXIDE (CD) She is a top insider with the Andreas Kalcker Institute, his ALK foundation, and their international umbrella organization, COMUSAV. Support the show Writer | Robert Yoho author

308. TANYA CARMONA DANIELS UPDATES US ABOUT CHLORINE DIOXIDE (CD) She is a top insider with the Andreas Kalcker Institute, his ALK foundation, and their international umbrella organization, COMUSAV. Support the show Writer | Robert Yoho author

S&P Futures are trading slightly lower this morning due to weakness in semiconductors. Markets are questioning the numbers and the timing of the recently announced Stargate Project. Key event today will be President Trump's speech today at Davos summit. Trump is schedule to speat at 11:00 am ET. His interview last night was rather uneventful as the focus was on his issues with former president Biden and FEMA. Central Bank meetings are on watch, the BOJ will make an announcement tomorrow, FOMC announcement on Jan 29th, and the ECB announcement is scheduled for Jan 30th. Earnings beats came in from ALK, DFS, GE, and MKC. After the bell today TXN and ISRG will report, and tomorrow morning AXP & VZ will report. European shares are mixed to higher & oil prices are higher by +0.50% this morning.

Dr. Evan Yu presents the new evidence-based guideline on genetic testing for metastatic prostate cancer. He discusses who should receive germline and somatic testing with next-generation sequencing technologies, what samples are preferred for testing, and the therapeutic & prognosistc impacts of genetic testing. Dr. Yu emphasizes the need for awareness and refers to areas of active investigation and future research to improve personalized therapies for patients with metastatic prostate cancer.  Read the full guideline, “Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline” at www.asco.org/genitourinary-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/genitourinary-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-24-02608 Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows, including this one at asco.org/podcasts. My name is Brittany Harvey and today I'm interviewing Dr. Evan Yu from the University of Washington and Fred Hutchinson Cancer Center, lead author on “Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline”. Thank you for being here today, Dr. Yu. Dr. Evan Yu: Thanks for having me on. Brittany Harvey: Great. Then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the entire guideline, including Dr. Yu, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, Dr. Yu, to start us off on the content of this guideline, could you first provide an overview of both the purpose and scope of this guideline? Dr. Evan Yu: Yeah, absolutely. So I think the one key thing to recognize is that prostate cancer is the highest incidence of all cancers in males. Additionally, it's the second highest cause of mortality in males, and that's about 35,000 deaths in 2024. So with that being said and done, it's a disease where we need to do better. And part of that is recognizing that we now have many targeted therapies, precision medicine type of therapies, but unlike a lot of other cancers out there, prostate cancer patients are not always getting sequencing, next generation DNA sequencing, let's say, to identify both inherited and also spontaneously develop what we call somatic mutations in their tumor. And I suspect that's partially because other cancers like breast cancer, we're so used to- in the first line, you present the patient, you throw out their estrogen receptor status, progesterone receptor status, HER2, ER/PR HER2; in lung cancer it's EGFR, ALK, ROS1, etc. In things like prostate cancer, things like BRCA2 have major important patient treatment implications and potentially family counseling and downstream cascade testing implications. But it hasn't made their way into that first-line presentation yet. And for that reason, there are some studies out there that show that testing in the community may be as low as 15% of patients with metastatic prostate cancer. We want to bring awareness to that and hopefully increase testing down the road so that we can better help our patients with metastatic prostate cancer. Brittany Harvey: Absolutely. It's important to get these targeted therapies to the patients who can benefit most. Using that context, I'd like to next review the key recommendations of this guideline across the six clinical questions that the panel addressed. So, starting with: Who should receive germline testing with next generation sequencing technologies? Dr. Evan Yu: Yeah. We think that it's common enough that everyone with metastatic prostate cancer should receive germline genetic testing. And the reason for that is there have been studies that have looked at this and have shown that 12% of men with metastatic prostate cancer have some sort of inherited germline mutation in a gene, mostly DNA repair genes. But 12% have something that is inherited and that loved ones, first degree relatives, siblings, offspring might have also inherited. Now, most of these are in the DNA repair genes, but that being said and done, there's not only treatment implications for the patient, where there are newer drugs that that patient could get treated with, but other loved ones that might have inherited these gene mutations, that these things can cause other cancers as well - not just prostate cancer, but breast cancer, endometrial cancer, ovarian cancer, pancreatic cancer. So, it's very important to test, with as high of an incidence as 12%, to test, and if you identify it in a patient, it's our job to talk to the patient about it and talk to them about the pros and cons of family counseling and talking to their loved ones and potentially having their loved ones get tested. Because if they test positive, then their doctors may want to know and may screen them very, very aggressively and differently for a whole host of other cancers. And the whole idea is you find the cancer very early and cure the patients before the cancer really takes hold and has the ability to spread so we can save a lot of lives down the road. Brittany Harvey: Absolutely. This germline testing is important not just for the patient, but has wider implications for their families as well, as you mentioned. So then, beyond those recommendations for germline testing, which patients should receive somatic testing with next-generation sequencing technologies? Dr. Evan Yu: So let's talk a little bit about somatic testing. So germline again, as we know, is inherited. The patient inherited it in every single cell in their body, then it becomes very easy, many of these are cancer predispositions for them to lose the other allele and then to have biallelic loss and then develop the cancer. Now, somatic just means it spontaneously occurred. Certainly, it's not going to occur in every cell in the body, but you can get one hit, lose one allele and then lose the other allele. And if that gene is truly carcinogenic and leading to that cancer, then that can have implications potentially for treatment as well. So we recommend that all patients with metastatic prostate cancer also undergo somatic next-generation sequencing testing. We recognize that at this point in time it's only those with metastatic castration-resistant prostate cancer or hormone-resistant prostate cancer, which is a later disease state where there are drugs that may target those mutations, for instance, like PARP inhibitors, but that early identification for a patient population that's fit and that can benefit from these therapies makes sense so that you know it's in place already and you have your treatments outlined and mapped out for the future. So we recommend it for everybody - somatic testing also for everyone with metastatic prostate cancer. Brittany Harvey: Understood. And then when patients are receiving that somatic testing, what is recommended for somatic testing? Primary tumor archival tissue? Fresh metastatic biopsy tissue? Or circulating tumor DNA testing? Dr. Evan Yu: We recommend that in the initial setting when you're first diagnosed, that archival tissue samples are fine and preferred. But circulating tumor DNA is good when there's no accessible archival tissue, or if the archival tissue, let's say, is very old and it's been sitting around for a long time, or you can't get it anymore because it's many years back when maybe a patient had a prostate needle biopsy. So if it's not accessible, then we recommend ctDNA. We believe that is preferred and also that ctDNA is recommended in a situation where you can't easily biopsy a metastatic site. Sometimes it's just not in a safe area to go after. Sometimes it's just a small lesion. So in general, we recommend tissue when available, and when we think that the tissue sample will yield clean results, if not, then we recommend doing ctDNA at that point in time. Brittany Harvey: So you have described who should get germline and somatic genomic testing. But what are the therapeutic impacts of this germline or somatic testing for single gene genetic variants? Dr. Evan Yu: We pulled this panel together and we met like every single month for like 12 months straight, and part of it was to review the literature. And as part of this literature review, we were able to pull a whole bunch of different trials. I think there was like 1713 papers we identified in the literature search. Eventually, we narrowed it down because with ASCO, we want to present the data with the highest level evidence, level 1 evidence, randomized controlled prospective data. And after reviewing 1713 papers, we narrowed it down to 14 papers. With those 14 papers, if you look at it, there are a lot of things that we think may have implications for treatment or prognosis, but we didn't feel was the highest level of evidence that we could support. So the things that have the highest level of evidence that we can support are certain DNA repair gene alterations, especially BRCA2, and treatment with PARP inhibitors because there are many PARP inhibitor prospective trials that show progression-free survival benefit and even overall survival benefit. And so that's the type of study that achieved the level of evidence that we could include. So I would say BRCA1 and BRCA2 highest level of evidence and PARP inhibitor use also is included in that. Brittany Harvey: Understood. I appreciate you reviewing those therapeutic options. So then, the last clinical question, which you just touched on briefly, but what are the prognostic impacts of germline and/or somatic testing? Dr. Evan Yu: Whenever you do testing, especially if you use panel testing, you find a lot of information. There's a lot of different mutations and some of which are VUSs (variants of unknown significance) where we don't quite know what it means yet, but we can track that, especially if it's germline. But with somatic, we find lots of things that have implications, but maybe just not treatment implications. A perfect example is p53. p53 is one of the most common tumor suppressor gene mutations on all cancers, but in prostate cancer they can occur and they can usually occur late, although there can even be germline inherited p53 alterations. There's no treatment that targets p53 right now, but we know that if you have a p53 mutation that those patients may have more aggressive disease and that prognostic information is important to give to the patient. And I think it's important for future clinical trial design and direction. So we do not recommend making treatment recommendations or changes based on these prognostic only biomarkers at this point in time. But we do recommend that, based on this, we can design intensification trials for those patients who have these poor risk biomarkers and de-intensification trials for patients who may have a good risk biomarker. So for instance, SPOP is a gene where we think these patients may have better outcomes, they might respond better to certain hormonal therapies like abiraterone. I say might because the level of evidence isn't quite there. But what I would say is that these prognostic only biomarkers, we just don't think they cut the mustard yet to be able to make treatment decisions. But we do think that they can drive counseling for the patient and potential selection and trial design for the future to say, “Okay. This is a patient population that has a more aggressive cancer. We need to be more aggressive in treating these patients.” “This patient population might have a less aggressive cancer. Maybe we can de-intensify and say side effects and quality of life may be better for the patients.” Brittany Harvey: Definitely. It's important for thinking through how to personalize care for these patients. So then you've talked about this a little bit in talking through the recommendations, but could you expand on what is the importance of this guideline and how it will impact both clinicians and patients with metastatic prostate cancer? Dr. Evan Yu: Yeah, I think the number one thing is awareness. I think the data's out there and people that are in my field, they know this. But by evidence of the fact that it's not first-line presentation lingo that everyone's talking about things like BRCA status, it means it hasn't necessarily disseminated all the way through. So it's increasing awareness of the fact that both germline and somatic alterations can occur and that these may have impacts on the patient for their treatment and their prognosis, and basically to increase testing for the future. I really think that in the future, there'll be other reasons that we may want to serially even retest and we may find that there may be mutations that develop as mechanisms of resistance that might guide therapy down the road. So we need to get people to start doing this for everyone with metastatic prostate cancer, because someday we might be doing it not just once, but over and over again. Brittany Harvey. Absolutely. We hope this guideline reaches a wide audience and that these recommendations can be put into practice. Finally, you've talked about how not all the data in the field has yet risen to the level of evidence that made it into the guidelines. So what are the outstanding questions in future research areas for both germline and somatic genomic testing for metastatic prostate cancer? Dr. Evan Yu: It was in our discussion, but it clearly- it's not common enough for there to be randomized prospective trials that would reach that level of evidence to make it in this guideline recommendation. But we all know that for any solid tumor, you can get mismatched repair deficiency, microsatellite instability leading to hypermutation or high tumor mutational burden. And that happens in maybe 3 to 5% of patients with metastatic prostate cancer as well. There is evidence and data that these patients can potentially benefit from immunotherapies like pembrolizumab. But again, it's just not common enough for there to be those randomized prospective controlled trials out there. But we mention it because we know it's FDA-approved across all the tumor types, so we felt like we have to mention it because that's something that has treatment implications for the patient. But also, I alluded to this earlier, I think an area of active investigation is the tried and true number one driver of prostate cancer, which is androgen receptor. Testosterone binds to androgen receptors, stimulates it. That's how androgen deprivation therapy works. That's how abiraterone and the amides like enzalutamide, apalutamide, darolutamide, that's how they all work. But even beyond that, we're starting to identify that maybe 15%, 20% of patients with metastatic castration resistant prostate cancer have androgen receptor mutations. And there are newer classes of therapies like androgen receptor degraders like CYP11A1 antagonist that lead to complete adrenal annihilation of other steroid hormones that might promiscuously stimulate these androgen receptor mutants. These things develop as mechanisms of resistance, and in the future, we might want to serially test- and that's an active area of investigation in the future, to say you've been treated, let's say, with androgen deprivation therapy and abiraterone for years. There are certain mutations that might develop as a resistance mechanism. We might need to serially test somebody because you didn't have that mutation earlier on, but later in the disease course you might. And then there might be a new drug X out there that we would want to use. Again, we need the data, we need the randomized prospective controlled trials, but they're happening out there. And somewhere down the road we may rewrite this guideline and have a lot more recommendations to add to it. Brittany Harvey: Yes, we'll look forward to more research in this field to better provide targeted therapies for patients with metastatic prostate cancer across the treatment paradigm. And we'll look forward to report outs from those trials that you mentioned. So I want to thank you so much for your work to develop this guideline and thank you for your time today, Dr. Yu. Dr. Evan Yu: Thank you so much. It's wonderful to be here today. Brittany Harvey: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/genitourinary-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

CME credits: 0.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/advancing-alk-inhibition-into-early-stage-nsclc-integrating-biomarker-driven-therapies-to-reduce-recurrence-risk-post-resection/27056/ This animated podcast explores the evolving role of ALK inhibitors in managing early-stage non-small cell lung cancer (NSCLC). Dr. Mark Socinski discusses molecular profiling as a cornerstone for identifying ALK fusion–positive cases and highlights clinical data from pivotal trials. He also addresses the challenges of treatment adherence, toxicity management, and the importance of surrogate endpoints in early-stage disease. The discussion concludes with key takeaways on integrating targeted therapies into standard care for early-stage resectable NSCLC.=

La Dre Nathalie Daaboul s'entretient avec Julie Desjardins de la vallée d'Annapolis, en Nouvelle-Écosse, dans notre premier épisode du balado en français Voix du cancer du poumon. Julie lutte contre un cancer du poumon ALK+ de stade IV depuis qu'elle a reçu un diagnostic inattendu en juillet 2022, alors qu'elle n'avait que 39 ans. Elle fait part de son histoire inspirante et de la façon dont le cancer a changé sa vision de la vie dans cet épisode.

In episode 81 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by Betsy Beggs of Goldman Sachs. At 23 years old, Betsy was a young professional finding her footing in New York City when she was blindsided by a stage 4 ALK+ lung cancer diagnosis. Tune in as she bravely shares her cancer story. For more, listen to Sarah Beggs, Betsy's mother, share her story from a parent perspective: youtu.be/05CrU4ltf80

Do you know the latest data on EGFR-mutated and ALK-positive non-small cell lung cancer (NSCLC)?   Credit available for this activity expires: 10/16/2025 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001752?ecd=bdc_podcast_libsyn_mscpedu

Featuring an interview with Dr Steven Horwitz, including the following topics: Overview of peripheral T-cell lymphomas (PTCLs) (0:00) Efficacy and safety of brentuximab vedotin in the management of treatment-naïve and relapsed PTCLs (9:57) Emerging therapeutic strategies for PTCLs (19:48) Case: A man in his early 50s with CD30-positive anaplastic large cell lymphoma who experienced complete response (CR) to BV-CHP and continued remission after consolidation with autologous stem cell transplant (ASCT) (25:53) Management of ALK-positive anaplastic large cell lymphoma (32:14) Case: A man in his late 50s with CD8-positive PTCL not otherwise specified who achieved CR with CHOEP and experienced relapse after ASCT (34:33) Case: A woman in her early 70s with chemorefractory CD30-positive angioimmunoblastic T-cell lymphoma (38:26) Ongoing first-line studies for T-cell lymphomas; association of CAR T-cell therapy with T-cell malignancies (42:18) CME information and select publications  

Dr Patil emphasized the significance of the phase 3 CROWN trial (NCT03052608), which compared lorlatinib (Lorbrena) with crizotinib (Xalkori) in patients with ALK-positive metastatic NSCLC. With a hazard ratio of 0.19 (95% CI, 0.13-0.27) for progression-free survival, the trial demonstrated lorlatinib's superior intracranial control and long-term efficacy compared with crizotinib, especially in patients with brain metastases. Drs Park and Patil also discussed challenges associated with managing lorlatinib-related toxicities, including mood changes, weight gain, and hyperlipidemia. Dr Patil suggested that starting at a lower dose and gradually escalating to the recommended dose could help mitigate some of these adverse effects and simultaneously maintain treatment efficacy. The conversation concluded with a shift towards the broader application of targeted therapies in earlier disease stages, drawing parallels between the phase 3 ALINA study (NCT03456076) in patients with ALK-positive

In this episode, Dr. Paul Wheatley-Price sits down with Dr. Geoffrey Liu, Medical Oncologist at Princess Margaret Cancer Center and a Canadian leader in opening dozens of clinical trials. Dr. Liu gives a rundown of everything you need to know about ALK-positive lung cancer - what is ALK, how common is it, how this type of lung cancer is treated, and some of the most recent clinical trial updates.

Featuring perspectives from Dr Ibiayi Dagogo-Jack and Dr Corey J Langer, including the following topics: Introduction: A Model for Targeted Treatment in Non-Small Cell Lung Cancer (NSCLC) (0:00) NSCLC with ALK, ROS1 and NTRK Rearrangements — Dr Langer (9:10) Current and Future Treatment of Metastatic NSCLC with RET, MET, HER2 and KRAS Alterations — Dr Dagogo-Jack (34:22) CME information and select publications

In today's episode, supported by AstraZeneca, we had the pleasure of speaking with Sandip P. Patel, MD, and Brendon M. Stiles, MD, about the FDA approval of perioperative durvalumab (Imfinzi) for patients with resectable non–small cell lung cancer (NSCLC). Dr Patel is a professor of medicine in the Department of Medicine at the University of California, San Diego. Dr Stiles is a professor of cardiothoracic surgery and chief of the Divisions of Thoracic Surgery and Surgical Oncology in the Department of Cardiothoracic & Vascular Surgery, as well as the associate director of Surgical Oncology at the Montefiore Einstein Comprehensive Cancer Center in Bronx, New York. On August 15, 2024, the FDA approved durvalumab plus platinum-containing chemotherapy in the neoadjuvant setting, followed by durvalumab monotherapy in the adjuvant setting, for the treatment of adult patients with resectable NSCLC with no known EGFR mutations or ALK rearrangements. This regulatory decision was backed by findings from the phase 3 AEGEAN trial (NCT03800134), in which the median event-free survival was not reached (95% CI, 31.9 months-not estimable [NE]) in patients who received the durvalumab regimen vs 25.9 months (95% CI, 18.9-NE) in those who received placebo plus chemotherapy (stratified HR, 0.68; 95% CI, 0.53-0.88; P = .0039). In our exclusive interview, Drs Patel and Stiles discussed the significance of this approval, key efficacy and safety findings from AEGEAN, and how the clinical use of perioperative treatment regimens reinforces the importance of involving multidisciplinary teams in every step of a patient's treatment plan.

Even though there are dozens of great value stocks, that doesn't mean you should own them all. (0:45) - Creating The Perfect Long-Term Portfolio: How Many Investments Should You Have? (9:00) - Tracey's Top Investments To Create A Manageable Individual Portfolio (27:20) - Episode Roundup: TAK, ALK, RNG

Even though there are dozens of great value stocks, that doesn't mean you should own them all. (0:45) - Creating The Perfect Long-Term Portfolio: How Many Investments Should You Have? (9:00) - Tracey's Top Investments To Create A Manageable Individual Portfolio (27:20) - Episode Roundup: TAK, ALK, RNG Podcast@Zacks.com

S&P Futures are displaying gains this morning as markets prepares for an ECB announcement on interest rates and this morning's data on Producer Prices. Jobless Claims are also on tap this morning, expectations are for a reading of 225,000. Tech stocks are showing gains. MRNA, NTGR and ALK, all released updated guidance data. After the bell today. ADBE is expected to release earnings. Norfolk Southern (NSC) is lower this morning as CEO was removed due to an improper relationship. An ECB announcement is expected at 8:15 am this morning. In Europe, markets are displaying strong gains, and oil prices are higher as Hurricane Francine is creating numerousness for oil futures.

In episode 76 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah travel to Indiana University in Bloomington to visit Sarah Beggs, Senior Vice President at the Indiana University Foundation. Tune in as Sarah shares how cancer became personal for her family as her daughter faced a stage 4 ALK+ lung cancer diagnosis.

It's been a busy old week at Turf Moor with the departures of Berge, Zaroury and Obafemi and the arrival of Humphreys and Worrall so there's plenty for the pod squad to discuss. Is this the ALK model in action? Where will it end? Is there more to come? Simon, Woody, Chris and Justin try to make sense of it all.Plus, Sunderland preview and Justin's ticketing woes. Hosted on Acast. See acast.com/privacy for more information.

Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting.

Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/InsideTheIssue2024/ALKPosNSCLC).

Talkin' ATLA with ALK! This has been one of our most requested topics and up until now it was exclusive to $10+ members of the patreon! Now it's free to the public. Enjoy!

Welcome to the Oncology Brothers Podcast! Join Drs. Rahul & Rohit Gosain in this episode as they welcome Dr. Balazs Halmos, a thoracic medical oncologist from Montefiore-Einstein Comprehensive Cancer Center, to discuss the current landscape of metastatic non-small cell lung cancer with actionable mutations in first-line settings. In this informative episode, they cover a wide range of topics including the importance of NGS testing, treatment options for various actionable mutations such as EGFR, ALK, ROS1, RET rearrangements, and more. Dr. Halmos provides valuable insights into decision-making processes, sequencing treatments, and managing toxicities associated with targeted therapies. Don't miss out on this insightful discussion that sheds light on the rapidly evolving space of precision medicine in lung cancer treatment. Stay informed and learn how identifying and targeting specific mutations can optimize treatment outcomes and improve patient quality of life. Tune in to the Oncology Brothers Podcast for expert insights and discussions on the latest developments in oncology. Subscribe now to stay updated on their informative episodes!

S&P Futures are positive this morning with gains in tech shares. Earnings are in focus today, last night report from TSM was positive, company raised guidance which is helping elevate the sector. this morning. Airline sector is weak as UAL & ALK guided lower yesterday. After the bell today NFLX is expected to report. Odds of President Biden leaving the race have increased over the last 24 hours. Also seeing earnings beats from ASML, JNJ, CFG & USB in the pre-market. Multiple Fed speakers today (Goolsbee, Logan & Daly) which will be their last comments before the July Fed meeting. In Europe, markets are higher ahead of an ECB announcement on monetary policy. Market anticipates two more rate cuts from the ECB this year. Oil prices are ticking lower as oil gives back some of yesterday's gains.

Drs. Balazs Halmos and Lecia Sequist delve into the groundbreaking updates from the 2024 ASCO Annual Meeting. With Chadi, they reveal game-changing insights on EGFR-mutated lung cancer from the LAURA trial, small-cell lung cancer upgrades from the ADRIATIC trial, important revelations in ALK mutation research, innovative combination therapies, ctDNA results from the ADAURA trial, and conclude with the relevance of the KRYSTAL-12 study. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

In this episode, hosts Drs. Rahul and Rohit Gosain are joined by special guest Dr. Joshua Sabari, a thoracic medical oncologist from NYU Langone Health. Together, they dive into the highlights from ASCO 2024, focusing on key studies in lung cancer. Here's a quick summary of what you can expect in this episode: •⁠  ⁠LAURA Trial: Discussing the use of Osimertinib as a consolidation approach after chemoradiation in unresectable stage 3 non-small cell lung cancer patients with common EGFR mutation. •⁠  ⁠MARIPOSA Study: Exploring the potential of Amivantamab and Lazertinib in common EGFR mutations. •⁠  ⁠CROWN Study and other ALK inhibitors: Alectinib, Lorlatinib, and Brigatinib for metastatic non-small cell lung cancer. •⁠  ⁠ADRIATIC Study: Examining the use of Durvalumab after concurrent chemoradiation in limited-stage small cell lung cancer. •⁠ PALOMA-3 Trial: Discussing subcutaneous Amivantamab vs. IV Amivantamab with Lazertinib Join the Oncology Brothers and Dr. Sabari as they break down these practice-changing studies and provide insights into the latest advancements in lung cancer treatment. Don't miss out on this informative and engaging discussion! Stay tuned for more ASCO 2024 highlights and updates on GI, GU, and breast cancer in the upcoming episodes. Subscribe to the Oncology Brothers Podcast for the latest in oncology news and research. Thank you for listening! Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

A proposed merger between Alaska Airlines and Hawaiian Airlines could help Alaska take market share over time. (00:21) Jason Moser and Deidre Woollard discuss: - The possibility of the Alaska Airlines and Hawaiian Airlines deal going through. - If airlines lose specialness as they grow. - The race to bring GLP-1 drugs to market. (18:35) Deidre Woollard chats with Solo Brands CEO John Merris about the company's collection of brands and where it could be headed next. Companies discussed: HA, ALK, AMZN, DTC, PFE, RHHBY Claim your dividend stocks here: www.fool.com/dividends Host: Deidre Woollard Guests: Jason Moser, John Merris Producer: Mary Long Engineers: Dan Boyd, Desiree Jones Learn more about your ad choices. Visit megaphone.fm/adchoices